Evotec SE
NASDAQ:EVO

  • LAST PRICE
    5.1000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    5.4600/ 24
  • Ask / Lots
    5.4900/ 7
  • Open / Previous Close
    --- / 5.1000
  • Day Range
    ---
  • 52 Week Range
    2.8500
    11.9999
  • Volume
    8,241

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Today

      Show headlines and story abstract

    • 24 minutes ago by Dow Jones
      Companies Mentioned: HALO

      By Maitane Sardon

      Shares in Evotec rose after the company said Thursday that it received a takeover offer from U.S. biotechnology company Halozyme Therapeutics for about 2 billion euros ($2.11 billion).

    • 1 hour ago by Dow Jones
      Companies Mentioned: HALO

      0809 GMT - It remains to be seen how Halozyme Therapeutics would fund a potential 2 billion-euro acquisition of German drug developer Evotec, RBC Capital Markets' analysts say in a research note. San Diego-based biopharmaceutical company Halozyme confirmed Thursday it submitted an all-cash bid of 11 euros a share for Evotec. The move means both industry and private-equity players have shown interest in Evotec. Private-equity firm Triton recently built a stake of about 10% in Evotec. This suggests Evotec's shares are depressed, but that there is significant value within the business that can be unlocked, RBC says. Shares in Evotec jump 22% to 10.56 euros. (adria.calatayud@wsj.com)

  • Yesterday

      Show headlines and story abstract

    • 10 hours ago by Dow Jones

      HAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (NASDAQ:EVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

    • 11 hours ago by Dow Jones
      Companies Mentioned: HALO

      By Sabela Ojea

      Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.)

    • 11 hours ago by MT Newswires
      Companies Mentioned: HALO, EVO
      05:15 PM EST, 11/14/2024 (MT Newswires) -- Halozyme Therapeutics (HALO) said Thursday it has made a non-binding proposal to buy Germany-based Evotec (EVO) for 11 euros ($11.58) per share in cash for a fully diluted equity value of 2 billion euros. T...

Peers Headlines

No documents available